Annexon (ANNX) Change in Accured Expenses (2019 - 2026)
Annexon (ANNX) posted quarterly Change in Accured Expenses of -$9.4 million for Q1 2026, down 421.22% year-over-year from $2.9 million in Q1 2025, and down 517.73% quarter-over-quarter from $2.2 million in Q4 2025.
Analysis
Annexon (ANNX) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Annexon's Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$9.4 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 421.22% year-over-year to -$9.4 million; the TTM figure through Mar 2026 stood at -$5.1 million (down 137.55% YoY), while the FY2025 annual figure was $7.2 million, down 0.95% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$9.4 million, down from $2.2 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $6.7 million in Q4 2024, with the low at -$9.4 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is $10000.0 (2022), against an average of $92941.2.
- Peak annual rise in Change in Accured Expenses reached 25350.0% in 2023, while the deepest fall reached 6796.0% in 2023.
- Annexon's Change in Accured Expenses stood at $10000.0 in 2022, then plunged by 6190.0% to -$609000.0 in 2023, then soared by 1201.31% to $6.7 million in 2024, then tumbled by 66.45% to $2.2 million in 2025, then plunged by 517.73% to -$9.4 million in 2026.
- Business Quant data shows ANNX's Change in Accured Expenses at -$9.4 million in Q1 2026, $2.2 million in Q4 2025, and -$3.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Annexon | 970.85 Mn | 970.85 Mn | - | 4.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.23 Mn |
| Mar 31, 2026 | -9.40 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | -3.87 Mn |
| Jun 30, 2025 | 5.92 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Dec 31, 2024 | 6.71 Mn |
| Sep 30, 2024 | 412,000.00 |
| Jun 30, 2024 | 3.54 Mn |
| Mar 31, 2024 | -3.37 Mn |
| Dec 31, 2023 | -609,000.00 |
| Sep 30, 2023 | 1.53 Mn |
| Jun 30, 2023 | -1.72 Mn |
| Mar 31, 2023 | -2.77 Mn |
| Dec 31, 2022 | 2.14 Mn |
| Sep 30, 2022 | 3.31 Mn |
| Jun 30, 2022 | 2.60 Mn |
| Mar 31, 2022 | -1.86 Mn |
| Dec 31, 2021 | 592,000.00 |
| Sep 30, 2021 | 828,000.00 |